Earlier this year, we took a look at the most common causes of drug-related recalls in 2022 and the first quarter of 2023. Now, we are expanding our lens to examine drug-related FDA recalls from 2011 to 2023. Understanding the recall landscape In recent decades, prominent incidents like the Tylenol poisonings in 1982 have underscored…

A federal judge ruled against two defendants accused of selling counterfeit HIV medications, denying their motions to lift existing asset freezes obtained by pharmaceutical company Gilead Sciences in the ongoing lawsuit. Judge Ann M. Donnelly of the United States District Court for the Eastern District of New York converted the temporary asset freezes into preliminary…

Preventing sudden failures and unexpected downtime in life sciences organizations starts with promoting a data-driven culture across the enterprise. Promoting a data-driven culture across the enterprise is what makes today’s most successful life sciences organizations stand out. Efficient operations are only possible when the processes underlying those activities are functional, and this type of reliable…

On October 12, 2022, the FDA confirmed what many patients with attention-deficit / hyperactivity disorder (ADHD) already knew: There was a shortage of the immediate-release formulation of amphetamine mixed salts commonly known by the brand name Adderall. The implications of this announcement have rippled across the United States, affecting scores of patients reliant on the…

Carbon tracking is a challenge in many industries, including the pharma sector. Companies are looking to manage their carbon emissions more effectively and meet their environmental, social and governance (ESG) goals, noted Maxence Cacheux, Zblocks co-founder and chief revenue officer. “They need to measure their internal carbon emissions (Scope 1), indirect emissions from the energy…

Qosina announced today that it’s appointed Lee Pochter as its executive vice president. Pochter has more than 20 years of expertise in product strategy, business development, sales, marketing and supply chain management. Most recently, he was VP of the Alternative Lens Group at EssilorLuxottica. “I look forward to the guidance Lee will bring to our…

Cardinal Health (NYSE:CAH) announced that it entered into a strategic collaboration with Palantir Technologies (NYSE:PLTR). The partnership pairs the companies to design a solution to give health systems and hospitals dynamic purchase decision insights. These insights help them quickly improve their bottom line. Dublin, Ohio-based Cardinal Health plans to integrate this solution into Foundry, Palantir’s…

Johnson & Johnson (NYSE:JNJ) today reported Q4 results that beat The Street on earnings but missed on revenue amid continued macroeconomic challenges. The company’s Pharmaceutical business saw sales grow 6.8%. Pharma growth drivers included: Darzalex (daratumumab), a biologic for the treatment of multiple myeloma; Stelara (ustekinumab), a biologic for the treatment of a number of…

Agilent recently announced that it plans to double its manufacturing capacity of therapeutic nucleic acids. The $725 million investment will go toward the Santa Clara, California–based company’s Frederick, Colorado facility. The Colorado plant will get new Train C and D manufacturing lines. The facility already has a Train B manufacturing line, announced in 2020, that…

Supplies of the ADHD drug Adderall (amphetamine and dextroamphetamine) remain limited, forcing millions of patients to either search multiple pharmacies, ration their medication, seek alternatives or deal with withdrawal symptoms. Half of the physicians have directly witnessed the Adderall shortage in their practices, according to a recent Sermo survey of 348 physicians. Demand for Adderall is increasing.…